# Fractionated Dosing Study: Study to Evaluate Darbepoetin Alfa for the Treatment of Anemia in Subjects With Non-Myeloid Malignancies

> **NCT00239239** · PHASE2 · COMPLETED · sponsor: **Amgen** · enrollment: 44 (actual)

## Conditions studied

- Non-Myeloid Malignancies
- Anemia
- Cancer

## Interventions

- **DRUG:** Darbepoetin alfa

## Key facts

- **NCT ID:** NCT00239239
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-08
- **Primary completion:** 2007-01
- **Final completion:** 2007-03
- **Target enrollment:** 44 (ACTUAL)
- **Last updated:** 2010-03-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00239239

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00239239, "Fractionated Dosing Study: Study to Evaluate Darbepoetin Alfa for the Treatment of Anemia in Subjects With Non-Myeloid Malignancies". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00239239. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*